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The field of neuroscience research in AD has been evolving rapidly over the last few years, and has pinpointed a
number of candidate targets for molecules with crucial role in the pathophysiology of AD. Recent developments
have furthermore enabled new ways of modeling the disease, while an increasing number of preclinically validated
targets is currently being taken one step forward and tested in clinical trials. These recent developments are
reviewed in the current Special Issues Series on “Current concepts in Alzheimer's disease research: molecules,
models and translational perspectives” in a number of state-of-the-art manuscripts.Text
In October 2012, a three-day workshop on “Emerging
Concepts in Alzheimer’s disease (AD)” was held in New
Orleans as a Satellite Meeting to the 2012 Society for
Neuroscience Meeting. The interactive workshop brought
together senior and junior scientists from the entire world
in a mixed format of interactive lectures and working
groups of scientists assigned to jointly design innovative
research projects, based on emerging concepts in AD as
introduced in the lectures (Figure 1). The current Special
issue Series in the journal is a direct product of the scien-
tific exchange and discussions during the workshop. The
Special Issue series comprises at least two Molecular
Neurodegeneration editions with state-of-the-art review
manuscripts by the teaching staff of the workshop, thereby
covering various topics and concepts that were discussed
during the workshop but also in post-workshop scientific
exchanges between the participants, i.e. students and
teaching staff.Molecules
Besides the well-known connections of the rare mutations
in genes encoding for amyloid precursor protein (APP)
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article, unless otherwise stated.(ApoE4) in the risk of AD, e.g. recent integrative genomic
analyses have described a distinct ApoE4-associated mo-
lecular pathway that promotes late-onset AD [1]. Recent
findings from large genome wide association studies
(GWAS) have furthermore shown evidence for associa-
tions between common variants in a set of genes, among
which CLU, CR1 and PICALM, and increased risk of spor-
adic AD [2,3], while next generation sequencing technolo-
gies and detailed bioinformatic analyses have furthermore
identified novel rare variants [4,5]. Environmental factors
such as a Mediterranean diet, physical exercise, and expos-
ure to toxins have been associated with AD, and it is likely
that environmental exposures during the entire lifespan
interact with genetic susceptibility in bringing about AD
in the elderly [6]. Neuropathological, genetic and molecu-
lar biologic evidence has thus accumulated over the last
years, and has given rise to a neurobiological theory on
the cascade of events with central roles for alterations in
the processing and metabolism of APP and tau protein,
resulting in aggregates of beta-amyloid (Aβ) fibrils and
neurofibrillary tangles. The Aβ cascade hypothesis has
been fuelled with biochemical studies in vitro and in vivo
studies on toxic properties of the different conformational
and differently polymerized states of Aβ aggregates, par-
ticularly at the synaptic level [7,8], and has reached a more
heuristic level with studies showing intricate crosstalk be-
tween misprocessing of beta-amyloid and tau proteins and
neuroinflammation, ultimately disturbing neuronal and
synaptic integrity and affecting cognitive functioning. A
role for neuroinflammatory responses has been proposed
in later phases of AD, but it has also been proposed thated Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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process by dysregulating mechanisms (for example at the
level of the blood-brain barrier; [9]) to clear misfolded or
damaged neuronal proteins [10,11] and heavy metals [12].
Based on recent studies indicating that dynamic changes
in epigenetic regulation of gene expression is involved in
many human (patho)physiological processes including
experience-dependent plasticity, neurogenesis and aging,
research efforts have been launched for studying epigen-
etic involvement in AD-associated neurodegeneration and
disturbances of neuroplasticity, see e.g. [13,14]. Evidence
from molecular and cellular studies have furthermore in-
dicated that age-related changes in mitochondrial ATP
production and oxidative stress are centrally involved in
the pathophysiology of AD [15], while evidence reviewed
by Walter et al. in the current issue suggests that mem-
brane lipids are involved in the regulation of subcellular
transport, activity, and metabolism of AD-related proteins,
and that vice versa, APP and other AD-associated proteins
impact on lipid metabolic pathways [16].
Models
It is clear that no animal model will ever fully capture the
complex human spectrum of molecular, cellular andfunctional abnormalities as seen in patients with AD, al-
beit that the use of animal models has been of crucial im-
portance for breakthroughs for our understanding of the
pathophysiology of AD [17]. Thus, animal models have
been necessary for the identification of causal relationships
of AD-related molecules, but they also offer the possibil-
ities for in vivo analyses of novel intervention strategies
[18]. Although transgenic mouse strains of AD are used
for the majority of animal studies in AD, recent advances in
the field of transgenesis have resulted into a current wave of
novel rat models of aberrant APP and tau processing, which
(among other advantages) enable improved behavioral
phenotyping [19]. The increasing demand for large and
high-throughput toxicity screens have also strengthened a
position for Drosophila melanogaster as a useful experimen-
tal animal species, and Pruessing et al. in the current issue
review the current status of Drosophila studies in relation
to AD [20]. Another model system with very high potential
for AD research is the use of inducible pluripotent stem
cells of AD patients for neuroscience research [21,22], on
which many developments are currently ongoing. Thus,
modeling AD-related disturbances in neurobiological path-
ways using in vivo and in vitro models has undergone quite
significant developments over the last few years.
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Despite the important open questions and unresolved
issues in elucidating the molecular and cellular mecha-
nisms at hand in sporadic AD cases, the AD research field
is very active (however not yet successful) in bringing
about therapeutic interventions that can potentially be
used in clinical practice.
For example, the field of immunotherapy in AD, after
finding striking effects of vaccinations in mouse models,
has been one of the prime areas for translational re-
search on therapeutic interventions over the last few
years. The current status of immunotherapy (with e.g.
active and passive immunization strategies) in rodent
and human AD studies is reviewed by Lemere [23], who
argues that (the immunological) intervention efforts
may need to be targeted to individuals at risk for AD,
rather than to late stage AD patients that for being ef-
fective, which off course goes hand in hand with im-
portant ethical challenges.
To summarize, AD research is expanding rapidly and
is reaching the phase in which findings from fundamen-
tal neuroscience drive the development of novel diag-
nostic and therapeutic strategies, hopefully resulting in
useful clinical tools to improve prevention and treat-
ment of this devastating neurodegenerative disorder in
the not-too-distant future.
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